Irritable bowel syndrome in the Russian Federation: results of the ROMERUS multicenter observational study
- Authors: Maev I.V.1, Okhlobystina O.Z.2, Khalif I.L.3, Andreev D.N.1
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Sechenov First Moscow State Medical University (Sechenov University)
- Ryzikh State Scientific Center for Coloproctology
- Issue: Vol 95, No 1 (2023)
- Pages: 38-51
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/133009
- DOI: https://doi.org/10.26442/00403660.2023.01.202043
- ID: 133009
Cite item
Full Text
Abstract
Background. Irritable bowel syndrome (IBS) is one of the most common functional disorders of the gastrointestinal tract. According to Russian guidelines, a standard examination using laboratory and instrumental evaluation methods, including colonoscopy, should be performed to establish the diagnosis of IBS.
Aim. To characterize the Russian population of IBS patients.
Materials and methods. A multicenter observational prospective study ROMERUS was conducted at 35 clinical centers in the Russian Federation. The study included male and female patients aged 18 to 50 with a diagnosis of IBS based on the Rome IV criteria, with no signs of structural gastrointestinal disease. The follow-up duration was 6 months and included three patients' visits to the study site. During the study, data were collected on patients' demographic and clinical characteristics, medical history, and drug therapy. The secondary parameters included the assessment of the proportion of patients with a diagnosis of IBS confirmed by a standard examination among all patients meeting the Rome IV criteria, the evaluation of the change over time of the IBS symptoms, quality of life (QoL), and adherence to therapy. Characterization of the population was performed using descriptive statistics methods. The standard examination results were presented as the percentage of patients with IBS confirmed by the standard examination among all patients meeting the Rome IV criteria, with a two-sided 95% confidence interval.
Results. The study included 1004 patients with a diagnosis of IBS according to the Rome IV criteria, with 790 (78.7%) patients included in the final analysis. The mean age of patients was 34.0±7.5 years; they were predominantly female (70.4%), Caucasian (99.4%), married (55.1%), urban residents (97.5%) with higher education (64.5%) and a permanent position (74.9%). Patients enrolled in the study have low physical activity and lack a healthy diet. The smoking rate was 26.3%. IBS symptoms with predominant constipation (IBS-C) were observed in 28.1% of patients; 28.9% had IBS with predominant diarrhea (IBS-D), 11.9% had mixed-type IBS, and 31.1% had non-classified IBS. The main IBS symptoms were pain (99.7%), abdominal distension (71.1%), and fullness (36.8%). Biliary tract dysfunction (18.9%) and gastritis (17.2%) were the most frequently reported comorbidities. Prior to enrollment, 28% of patients received drug therapy. The most commonly prescribed drug during the study was mebeverine (54.1%). At 6 months of follow-up, there was a significant reduction of abdominal pain, bloating, and distention, and a twofold reduction in the incidence of constipation and diarrhea in the subgroups of patients with IBS-C and IBS-D, respectively. The overall QoL score measured by the IBS-QoL questionnaire increased from 83.0 to 95.2 points (p<0.05) during the study. In the overall assessment of their condition, 69.6% of patients noted no symptoms and 25.3% reported marked improvement, 35% were asymptomatic according to the physician's overall assessment of the patient's condition, and 51.8% showed significant improvement.
Conclusion. IBS patients in the Russian Federation were characterized. The diagnosis of IBS, established following the Rome IV criteria, is confirmed by the results of a standard examination in 96.3% of patients. The Rome IV criteria for the IBS diagnosis make it possible to establish a diagnosis with a probability of 94.7%. For 6 months of follow-up, there was a clinical improvement with a decrease in the severity of symptoms and a QoL improvement.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Igor V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Email: dna-mit8@mail.ru
ORCID iD: 0000-0001-6114-564X
акад. РАН, д-р мед. наук, проф., зав. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowOlga Z. Okhlobystina
Sechenov First Moscow State Medical University (Sechenov University)
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-2766-7070
канд. мед. наук, врач-гастроэнтеролог Клиники пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко
Russian Federation, MoscowIgor L. Khalif
Ryzikh State Scientific Center for Coloproctology
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-2014-6299
д-р мед. наук, проф., рук. отд. по изучению воспалительных и функциональных заболеваний кишечника
Russian Federation, MoscowDmitry N. Andreev
Yevdokimov Moscow State University of Medicine and Dentistry
Author for correspondence.
Email: dna-mit8@mail.ru
ORCID iD: 0000-0002-4007-7112
канд. мед. наук, доц., доц. каф. пропедевтики внутренних болезней и гастроэнтерологии
Russian Federation, MoscowReferences
- Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80. doi: 10.2147/CLEP.S40245
- Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-21.e4. doi: 10.1016/j.cgh.2012.02.029
- Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28(10):1726-11. doi: 10.1016/j.clinthera.2006.10.010
- Smith GD, Steinke DT, Kinnear M, et al. A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. Br J Gen Pract. 2004;54:503-7.
- Everhart JE, Ruhl CE. Burden of digestive diseases in the United States, part II: lower gastrointestinal diseases. Gastroenterology. 2009;136(3):741-54. doi: 10.1053/j.gastro.2009.01.015
- Grodzinsky E, Hallert C, Faresjö T, et al. Could gastrointestinal disorders differ in two close but divergent social environments? Int J Health Geogr. 2012;11:5. doi: 10.1186/1476-072X-11-5
- Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNβ3 825C& gt; T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS). Dig Dis Sci. 2012;57:2650-7. doi: 10.1007/s10620-012-2319-9
- Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastoenterol. 2014;20(10):2470-81. doi: 10.3748/wjg.v20.i10.2470
- Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2012;303(7):G775-85. doi: 10.1152/ajpgi.00155.2012
- Kanazawa M, Endo M, Yamaguchi K, et al. Classical conditioned response of rectosigmoid motility and regional cerebral activity in humans. Neurogastroenterol Motil. 2005;17:705-13. doi: 10.1111/j.1365-2982.2005.00691.x
- Labus JS, Naliboff BD, Berman SM, et al. Brain networks underlying perceptual habituation to repeated aversive visceral stimuli in patients with irritable bowel syndrome. Neuroimage. 2009;47:952-60. doi: 10.1016/j.neuroimage.2009.05.078
- Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11:S17-26.
- Lacy BE, Mearin F, Chang L, et al. Bowel Disorders. Gastroenterology. 2016;150:1393-407. doi: 10.1053/j.gastro.2016.02.031
- Spiegel BM, Farid M, Esrailian E, et al. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010;105:848-58. doi: 10.1038/ajg.2010.47
- Seifert B, Rubin G, de Wit N, et al. The management of common gastrointestinal disorders in general practice: a survey by the European Society for Primary Care Gastroenterology (ESPCG) in six European countries. Dig Liver Dis. 2008;40:659-66. doi: 10.1016/j.dld.2008.02.020
- Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104(Suppl. 1):S1-35. doi: 10.1038/ajg.2008.122
- Chey WD, Nojkov B, Rubenstein JH, et al. The yield of colonoscopy in patients with non-constipated irritable bowel syndrome: results from a prospective, controlled US trial. Am J Gastroenterol. 2010;105:859-65. doi: 10.1038/ajg.2010.55
- Cash BD, Rubenstein JH, Young PE, et al. The prevalence of celiac disease among patients with nonconstipated irritable bowel syndrome is similar to controls. Gastroenterology. 2011;141:1187-93. doi: 10.1053/j.gastro.2011.06.084
- Cash BD, Schoenfeld P, Chey WD. The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review. Am J Gastroenterol. 2002;97:2812-9. doi: 10.1016/S0002-9270(02)05444-8
- Begtrup LM, Engsbro AL, Kjeldsen J, et al. A positive diagnostic strategy is noninferior to a strategy of exclusion for patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:956-62. doi: 10.1016/j.cgh.2012.12.038
- Ford AC, Talley NJ, Veldhuyzen van Zanten SJ, et al. Will the history and physical examination help establish that irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300:1793-805. doi: 10.1001/jama.300.15.1793
- Ford AC, Bercik P, Morgan DG, et al. Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology. 2013;145:1262-70. doi: 10.1053/j.gastro.2013.08.048
- Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? Expert Rev Gastroenterol Hepatol. 2017;11:4:281-3. doi: 10.1080/17474124.2017.1292130
- Ивашкин В.Т., Шелыгин Ю.А., Баранская Е.К., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2017;27(5):76-93 [Ivashkin VT, Shelygin YuA, Baranskaya YeK, et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93 (in Russian)]. doi: 10.22416/1382-4376-2017-27-5-76-93
- Dumitrascu DL, Babin A, Bordin DS, et al. Recent Data on Irritable Bowel Syndrome from some Central and East European Countries. J Gastrointestin Liver Dis. 2020;29(2):247-50. doi: 10.15403/jgld-2407
- Фофанова Т.В., Агеев Ф.Т., Смирнова М.Д., и др. Отечественный опросник приверженности терапии: апробация и применение в амбулаторной практике. Системные гипертензии. 2014;11(2):13-6 [Fofanova TV, Ageev FT, Smirnova MD, et al. National questionnaire of treatment compliance: testing and application in outpatient practice. Systemic Hypertension. 2014;11(2):13-6 (in Russian)].
- Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol. 2012;107(7):991-1000. doi: 10.1038/ajg.2012.131
- Gwee KA. Irritable bowel syndrome in developing countries: a disorder of civilization or colonization? Neurogastroenterol Motil. 2005;17(3):317-24. doi: 10.1111/j.1365-2982.2005.00627.x
- Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am. 2005;34(2):189-204. doi: 10.1016/j.gtc.2005.02.008
- Drossman DA, Morris CB, Schneck S, et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol. 2009;43(6):541-50. doi: 10.1097/MCG.0b013e318189a7f9
- Silk DB. Impact of irritable bowel syndrome on personal relationships and working practices. Eur J Gastroenterol Hepatol. 2001;13:1327-32.
- Guo YB, Zhuang KM, Kuang L, et al. Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study. Gut Liver. 2015;9(5):649-56. doi: 10.5009/gnl13437
- Ikechi R, Fischer BD, DeSipio J, Phadtare S. Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. Healthcare (Basel). 2017;5(2):21. doi: 10.3390/healthcare5020021
- Miwa H. Life style in persons with functional gastrointestinal disorders: large-scale internet survey of lifestyle in Japan. Neurogastroenterol Motil. 2012;24:464-71.e217. doi: 10.1111/j.1365-2982.2011.01872.x
- Drossman DA. Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome? Am J Med. 1999;107:41S-50S. doi: 10.1016/S0002-9343(99)00081-9
- Locke GR 3rd, Zinsmeister AR, Talley NJ, et al. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc. 2000;75(9):907-12. doi: 10.4065/75.9.907
- Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology. 2001;121(4):799-804. doi: 10.1053/gast.2001.27995
- Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol. 1998;93(8):1311-7. doi: 10.1016/S0002-9270(98)00321-9
- Hou X, Chen S, Zhang Y, et al. Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China. Clin Drug Investig. 2014;34(11):783-93. doi: 10.1007/s40261-014-0233-y
- Mearin F, Balboa A, Badia X, et al. Irritable bowel syndrome subtypes according to bowel habit: revisiting the alternating subtype. Eur J Gastroenterol Hepatol. 2003;15:165-72.
- WGO Practice Guideline – Irritable Bowel Syndrome (IBS). Update September 2015. Available: https://www.worldgastroenterology.org/guidelines/global-guidelines/irritable-bowel-syndrome-ibs. Accessed: 01.12.2022.
- Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology. 2002;122:1140-56. doi: 10.1053/gast.2002.32392
- von Wulffen M, Talley NJ, Hammer J, et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci. 2019;64(2):480-6. doi: 10.1007/s10620-018-5343-6
- Осипенко М.Ф., Бут-Гусаим В.И., Волошина Н.Б., Бикбулатова Е.А. Синдром «перекреста»: синдром раздраженного кишечника и функциональные расстройства билиарного тракта. Сибирский медицинский журнал (Иркутск). 2008;80(5):21-6 [Osipenko MF, But-Gusaim VI, Voloshina NB, Bikbulatova EA. “Overlap syndrome”: irritable bowel syndrome and functional gallbladder and sphincter of Oddi disorders. Siberian Medical Journal (Irkutsk). 2008;80(5):21-6 (in Russian)].
- McNally MA, Locke GR, Zinsmeister AR, et al. Biliary events and an increased risk of new onset irritable bowel syndrome: a population-based cohort study. Aliment Pharmacol Ther. 2008;28(3):334-43. doi: 10.1111/j.1365-2036.2008.03715.x
- Kennedy TM, Jones RH. Epidemiology of cholecystectomy and irritable bowel syndrome in a UK population. Br J Surg. 2000;87(12):1658-63. doi: 10.1046/j.1365-2168.2000.01596.x
- Hasler WL, Schoenfeld P. Systematic review: abdominal and pelvic surgery in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2003;17:997-1005. doi: 10.1046/j.1365-2036.2003.01499.x
- Evans PR, Dowsett JF, Bak YT, et al. Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci. 1995;40(5):1149-56. doi: 10.1007/BF02064214
- Guliter S, Yilmaz S, Yakaryilmaz F, Keles H. Evaluation of gallbladder motility in patients with irritable bowel syndrome. Swiss Med Wkly. 2005;135(27-8):407-11.
- Güçlü M, Pourbagher A, Serin E, et al. Ultrasonographic evaluation of gallbladder functions in patients with irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21(8):1309-12. doi: 10.1111/j.1440-1746.2006.04136.x
- Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl. 1):S2-26;quiz S27. doi: 10.1038/ajg.2014.187
- Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol. 2010;16(5):547-53. doi: 10.3748/wjg.v16.i5.547
- Boisson J, Coudert Ph, Dupuis J, et al. Tolerance de la mebeverine a long terme. Act Ther. 1987;16:289-92.
- Kawanawa M, Drossman DA, Shonozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome quality of life measure (IBS-QOL–J). BioPsychoSoc Med. 2007;1:6. doi: 10.1007/s40261-014-0233-y
Supplementary files
![](/img/style/loading.gif)